RESEARCH IN INDIA HAS EVEN FOUND THAT ONE-TWELFTH OF THE STANDARD NIVOLUMAB DOSE MAY BE EFFECTIVE.
DRUGMAKERS, HOSPITALS, AND PHYSICIANS HAVE FINANCIAL INCENTIVES TO MAINTAIN HIGHER DOSING
ONE ESTIMATE SUGGESTS THE U.S. COULD HAVE SAVED ROUGHLY $31 BILLION IN 2024 BY USING THE LOWEST EFFECTIVE DOSES OF 29 EXPENSIVE CANCER DRUGS.
To restore balance, academic medical centers should refocus on education, research, and public service; protect trainees from purely profit-driven pressures; and promote physician-leaders who remain directly engaged in patient care and teaching.
More than a century after the Flexner Report warned about commercialization in medicine, business priorities again threaten to overshadow the core mission of academic medicine: patient care, education, and scientific discovery.
Big investors are buying hospitals, nursing homes, and doctor’s practices. This can bring money and technology—but often puts profits over patients.
Costs up, quality down: Private equity nursing homes have worse staffing and outcomes. Hospital mergers drive prices up.
Doctors under pressure: Loopholes let corporations control practices behind the scenes.
Solutions: Transparency on ownership, quality standards, smarter Medicare/Medicaid rules, and stronger oversight.
